Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares saw an uptick in trading volume on Tuesday . 4,963,232 shares changed hands during mid-day trading, an increase of 24% from the previous session’s volume of 3,995,517 shares.The stock last traded at $8.14 and had previously closed at $8.20.

A number of research firms recently commented on ARIA. Cowen and Company reiterated a “hold” rating on shares of Ariad Pharmaceuticals in a research note on Sunday, April 17th. Zacks Investment Research downgraded Ariad Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 4th. Barclays PLC lifted their target price on Ariad Pharmaceuticals from $6.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, May 11th. William Blair restated a “buy” rating and issued a $10.00 target price on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $9.06.

The firm’s 50 day moving average price is $7.63 and its 200-day moving average price is $6.72. The firm’s market cap is $1.58 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings results on Tuesday, May 10th. The pharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.04. The firm had revenue of $35.60 million for the quarter, compared to analyst estimates of $43.06 million. During the same period in the prior year, the firm earned ($0.28) EPS. The firm’s revenue was up 48.3% on a year-over-year basis. Equities analysts forecast that Ariad Pharmaceuticals Inc. will post ($0.73) EPS for the current year.

In related news, CEO Paris Panayiotopoulos acquired 26,990 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $7.41 per share, with a total value of $199,995.90. Following the completion of the transaction, the chief executive officer now owns 61,099 shares of the company’s stock, valued at $452,743.59. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy P. Clackson sold 18,286 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $8.11, for a total transaction of $148,299.46. Following the transaction, the insider now directly owns 248,208 shares of the company’s stock, valued at approximately $2,012,966.88. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in ARIA. California State Teachers Retirement System raised its position in shares of Ariad Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 310,276 shares of the pharmaceutical company’s stock worth $1,939,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers raised its position in shares of Ariad Pharmaceuticals by 7.8% in the fourth quarter. Rhumbline Advisers now owns 174,193 shares of the pharmaceutical company’s stock worth $1,089,000 after buying an additional 12,560 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Ariad Pharmaceuticals by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 176,600 shares of the pharmaceutical company’s stock worth $1,104,000 after buying an additional 16,552 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Ariad Pharmaceuticals by 18.0% in the fourth quarter. New York State Common Retirement Fund now owns 193,180 shares of the pharmaceutical company’s stock worth $1,207,000 after buying an additional 29,480 shares in the last quarter. Finally, OppenheimerFunds Inc. raised its position in shares of Ariad Pharmaceuticals by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 1,862,400 shares of the pharmaceutical company’s stock worth $11,640,000 after buying an additional 9,480 shares in the last quarter.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.